AbbVie Stock Will Hit $300 on This Date

AbbVie reported Q1 2026 revenue growth of 12.4% YoY, led by immunology sales of $7.29B, with Skyrizi up 30.9% and Rinvoq up 23.3%. Management raised full-year guidance to $14.08-$14.28, though reported net income fell 45.96% due to a $744M acquired IPR&D charge and legacy declines in Humira (-38.6%) and Imbruvica (-24.7%). The stock trades at $221.59, about 14.4% below the consensus target of $253.55, with a long-term bull case arguing for $300 by 2030.

Analysis

AbbVie is behaving like a de-risked compounder that the market still prices as a melting maturity story. The key second-order effect is that every dollar of next-gen immunology and neuroscience growth reduces the market’s willingness to capitalize legacy erosion at a punitive multiple; if that mix shift persists, multiple expansion can happen even without heroic top-line acceleration. In other words, the equity doesn’t need a breakthrough — it needs the market to stop treating transition costs as structural impairment.

The biggest misread is likely on earnings quality. IPR&D charges are volatility in reported GAAP, but they are also a signal that management is still buying duration for the franchise; that tends to compress near-term multiples while improving the long runway. Meanwhile, the legacy declines matter less than the pace of offset: the real risk is not that Humira or Imbruvica keep falling, but that their run-off outpaces the cadence of new-product contribution during the next 4-6 quarters, which would cap the stock in a low-teens multiple band.

Catalysts are mostly medium-term: another clean quarter of 20%+ growth in Skyrizi/Rinvoq, a visible moderation in acquisition-related charges, and evidence that neuroscience can become a second pillar rather than a side story. If those three line up, a 22-23x forward multiple is plausible on sentiment alone, which makes $300 more about rerating than earnings heroics. The contrarian angle is that this may already be a quality compounder with a valuation still anchored to old-franchise decay; consensus may be underestimating how quickly investors can reclassify it once reported EPS and adjusted EPS converge.

Key Decisions for Investors

• Go long ABBV on 3-6 month horizon into any post-earnings weakness; target a rerating toward 20-22x forward EPS if adjusted/GAAP noise narrows. Use a tight stop below the recent range lows because the setup depends on sentiment normalization, not just fundamentals.
• Buy ABBV Jan-2027 calls or call spreads to express the multi-year $300 thesis with defined risk. Favor spreads to reduce premium bleed, since the catalyst path is gradual and the stock already screens as low-volatility.
• Pair trade: long ABBV / short a basket of higher-beta healthcare names with weaker earnings quality, capturing the market’s preference for durable cash generation over narrative-only growth. This isolates the valuation reclassification trade while dampening sector risk.
• If you want a tactical entry, wait for the next quarter and buy only if next-gen growth remains above 20% and GAAP charges normalize sequentially. That is the point where the market is most likely to stop discounting the transition.
• Do not short ABBV solely on legacy-drug erosion unless you have a stronger thesis on new-product deceleration; the asymmetry favors the long side because downside is already constrained by defensive ownership and valuation support.